Track topics on Twitter Track topics that are important to you
Boehringer Ingelheim announced that it had broken ground on its planned $217 million upgrade and expansion of its existing Fermont manufacturing facility. The investment is expected to create a further 300 jobs to the city of Fremont, just south of San Francisco.
The facility produces biologics and biosimilars, with a focus on oncology, rheumatology and immunology. Should the expansion be carried out as planned, the production capability of the plant will be boosted by a third.
Original Article: Boehringer Ingelheim break ground on $217 million Fremont facilityNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...